Is Beam Therapeutics Stock a Good Investment?
Beam Therapeutics Investment Advice | BEAM |
- Examine Beam Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Beam Therapeutics' leadership team and their track record. Good management can help Beam Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Beam Therapeutics' business and its evolving consumer preferences.
- Compare Beam Therapeutics' performance and market position to its competitors. Analyze how Beam Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Beam Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Beam Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Beam Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Beam Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Beam Therapeutics Stock
Researching Beam Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 93.0% of the company shares are held by institutions such as insurance companies. The book value of Beam Therapeutics was currently reported as 9.97. The company recorded a loss per share of 1.58. Beam Therapeutics last dividend was issued on the February 4, 2014. The entity had 2:1 split on the October 26, 1990.
To determine if Beam Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Beam Therapeutics' research are outlined below:
| Beam Therapeutics generated a negative expected return over the last 90 days | |
| Beam Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 377.71 M. Net Loss for the year was (132.53 M) with loss before overhead, payroll, taxes, and interest of (250.67 M). | |
| Beam Therapeutics currently holds about 1.09 B in cash with (149.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.9. | |
| Beam Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3 |
Beam Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Beam Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Beam Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Beam Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Beam Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-11-10 | 2020-09-30 | -0.56 | -0.69 | -0.13 | 23 | ||
2023-11-08 | 2023-09-30 | -1.36 | -1.22 | 0.14 | 10 | ||
2020-08-12 | 2020-06-30 | -0.53 | -0.69 | -0.16 | 30 | ||
2024-05-07 | 2024-03-31 | -1.42 | -1.21 | 0.21 | 14 | ||
2022-11-07 | 2022-09-30 | -1.31 | -1.56 | -0.25 | 19 | ||
2022-05-09 | 2022-03-31 | -1.32 | -1.01 | 0.31 | 23 | ||
2021-11-08 | 2021-09-30 | -0.74 | -0.42 | 0.32 | 43 | ||
2023-08-08 | 2023-06-30 | -1.42 | -1.08 | 0.34 | 23 |
Know Beam Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Beam Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Beam Therapeutics backward and forwards among themselves. Beam Therapeutics' institutional investor refers to the entity that pools money to purchase Beam Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-06-30 | 1.7 M | Redmile Group, Llc | 2024-09-30 | 1.6 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.6 M | Bellevue Group Ag | 2024-09-30 | 1.5 M | First Trust Advisors L.p. | 2024-06-30 | 1.5 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.4 M | Kynam Capital Management, Lp | 6024-09-30 | 1.3 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.2 M | Deutsche Bank Ag | 2024-06-30 | 862 K | Farallon Capital Management, L.l.c. | 2024-06-30 | 7.9 M | Vanguard Group Inc | 2024-09-30 | 7.8 M |
Beam Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.03 B.Market Cap |
|
Beam Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.09) | (0.10) | |
| Return On Capital Employed | (0.14) | (0.13) | |
| Return On Assets | (0.09) | (0.10) | |
| Return On Equity | (0.14) | (0.14) |
Determining Beam Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Beam Therapeutics is a good buy. For example, gross profit margin measures Beam Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Beam Therapeutics' profitability and make more informed investment decisions.
Beam Therapeutics' Earnings Breakdown by Geography
Evaluate Beam Therapeutics' management efficiency
Beam Therapeutics has return on total asset (ROA) of (0.0928) % which means that it has lost $0.0928 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1829) %, meaning that it created substantial loss on money invested by shareholders. Beam Therapeutics' management efficiency ratios could be used to measure how well Beam Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -0.1. In addition to that, Return On Capital Employed is likely to grow to -0.13. At this time, Beam Therapeutics' Other Current Assets are very stable compared to the past year. As of the 22nd of November 2024, Total Current Assets is likely to grow to about 1.3 B, while Non Current Assets Total are likely to drop about 193.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 12.72 | 13.36 | |
| Tangible Book Value Per Share | 12.72 | 13.36 | |
| Enterprise Value Over EBITDA | (11.74) | (12.33) | |
| Price Book Value Ratio | 2.14 | 2.25 | |
| Enterprise Value Multiple | (11.74) | (12.33) | |
| Price Fair Value | 2.14 | 2.25 | |
| Enterprise Value | 1.8 B | 3.5 B |
Evaluating the management effectiveness of Beam Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Beam Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 1.862 |
Basic technical analysis of Beam Stock
As of the 22nd of November, Beam Therapeutics shows the risk adjusted performance of 0.0233, and Mean Deviation of 3.08. Beam Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Beam Therapeutics jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Beam Therapeutics is priced correctly, providing market reflects its regular price of 23.58 per share. Given that Beam Therapeutics has jensen alpha of (0.22), we suggest you to validate Beam Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.Beam Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Beam Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Beam Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Beam Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Beam Therapeutics' Outstanding Corporate Bonds
Beam Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Beam Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Beam bonds can be classified according to their maturity, which is the date when Beam Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Beam Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Beam Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0233 | |||
| Market Risk Adjusted Performance | 0.0317 | |||
| Mean Deviation | 3.08 | |||
| Semi Deviation | 3.59 | |||
| Downside Deviation | 3.66 | |||
| Coefficient Of Variation | 5002.14 | |||
| Standard Deviation | 4.24 | |||
| Variance | 17.94 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | (0.22) | |||
| Total Risk Alpha | (0.41) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0217 | |||
| Maximum Drawdown | 20.75 | |||
| Value At Risk | (7.94) | |||
| Potential Upside | 7.79 | |||
| Downside Variance | 13.37 | |||
| Semi Variance | 12.92 | |||
| Expected Short fall | (3.59) | |||
| Skewness | 0.5671 | |||
| Kurtosis | 1.07 |
| Risk Adjusted Performance | 0.0233 | |||
| Market Risk Adjusted Performance | 0.0317 | |||
| Mean Deviation | 3.08 | |||
| Semi Deviation | 3.59 | |||
| Downside Deviation | 3.66 | |||
| Coefficient Of Variation | 5002.14 | |||
| Standard Deviation | 4.24 | |||
| Variance | 17.94 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | (0.22) | |||
| Total Risk Alpha | (0.41) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0217 | |||
| Maximum Drawdown | 20.75 | |||
| Value At Risk | (7.94) | |||
| Potential Upside | 7.79 | |||
| Downside Variance | 13.37 | |||
| Semi Variance | 12.92 | |||
| Expected Short fall | (3.59) | |||
| Skewness | 0.5671 | |||
| Kurtosis | 1.07 |
Consider Beam Therapeutics' intraday indicators
Beam Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Beam Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 56419.38 | |||
| Daily Balance Of Power | (0.66) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 24.02 | |||
| Day Typical Price | 23.87 | |||
| Price Action Indicator | (0.90) | |||
| Period Momentum Indicator | (0.91) | |||
| Relative Strength Index | 47.57 |
Beam Therapeutics Corporate Filings
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 16th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 19th of August 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Beam Stock media impact
Far too much social signal, news, headlines, and media speculation about Beam Therapeutics that are available to investors today. That information is available publicly through Beam media outlets and privately through word of mouth or via Beam internal channels. However, regardless of the origin, that massive amount of Beam data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Beam Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Beam Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Beam Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Beam Therapeutics alpha.
Beam Therapeutics Corporate Management
| Manmohan Singh | Chief Officer | Profile | |
| Nicole Gaudelli | CoFounder | Profile | |
| Brian Riley | VP Operations | Profile | |
| Susan OConnor | Chief Officer | Profile | |
| Alexis Komor | CoFounder | Profile | |
| Amy MD | Chief Officer | Profile | |
| Suzanne Fleming | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share 4.273 | Quarterly Revenue Growth (0.17) | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Beam Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.